erlotinib has been researched along with afimoxifene in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (afimoxifene) | Trials (afimoxifene) | Recent Studies (post-2010) (afimoxifene) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 1,255 | 10 | 325 |
| Protein | Taxonomy | erlotinib (IC50) | afimoxifene (IC50) |
|---|---|---|---|
| Phospholipase D2 | Homo sapiens (human) | 6.5 | |
| Estrogen receptor | Homo sapiens (human) | 0.0105 | |
| Estrogen-related receptor gamma | Homo sapiens (human) | 0.0084 | |
| Phospholipase D1 | Homo sapiens (human) | 6.5 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.0102 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arya, GC; Jaitak, V; Kaur, K | 1 |
1 review(s) available for erlotinib and afimoxifene
| Article | Year |
|---|---|
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles | 2021 |